Calaris Suspensionskoncentrat デンマーク - デンマーク語 - SEGES Landbrug & Fødevarer

calaris suspensionskoncentrat

syngenta nordics a/s - mesotrion, terbuthylazin - suspensionskoncentrat - 70 g/l mesotrion ; 330 g/l terbuthylazin

Ryaltris 25+600 mikrog./dosis næsespray, suspension デンマーク - デンマーク語 - Lægemiddelstyrelsen (Danish Medicines Agency)

ryaltris 25+600 mikrog./dosis næsespray, suspension

glenmark pharmaceuticals s.r.o. - mometasonfuroat monohydrat, olopatadinhydrochlorid - næsespray, suspension - 25+600 mikrog./dosis

Ryaltris 25+600 mikrog./dosis næsespray, suspension デンマーク - デンマーク語 - Lægemiddelstyrelsen (Danish Medicines Agency)

ryaltris 25+600 mikrog./dosis næsespray, suspension

paranova danmark a/s - mometasonfuroat monohydrat, olopatadinhydrochlorid - næsespray, suspension - 25+600 mikrog./dosis

Calaris, reg.nr. 650-10 Suspensionskoncentrat デンマーク - デンマーク語 - SEGES Landbrug & Fødevarer

calaris, reg.nr. 650-10 suspensionskoncentrat

agros - mesotrion, terbuthylazin - suspensionskoncentrat - 70 g/l mesotrion ; 330 g/l terbuthylazin

Opdualag 欧州連合 - デンマーク語 - EMA (European Medicines Agency)

opdualag

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanom - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.